Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
MicroRNAs (miRNAs) are vital for post-transcriptional gene regulation, affecting numerous cellular processes and implicated in various diseases. Creative Biogene offers miRNA expression plasmids covering the human genome, available for direct transfection or viral delivery via adenovirus/lentivirus. Our vectors feature CMV-driven miRNA precursors with GFP as a transduction efficiency reporter, ensuring efficient transduction and high-level expression. Explore our miRNA viral vector collection and leverage our cloning services for customized solutions.
Key Features of Our miRNA Viral Vectors
Viral vectors, including retroviral, lentiviral, and adeno-associated viral (AAV) vectors, are utilized for efficient delivery of miRNAs into target cells. These vectors can transfect both dividing and non-dividing cells, with options for precise delivery to specific organ locations. Adenovirus, AAV, and lentivirus are commonly employed for delivering pre-miRNAs or mature miRNAs into cells, enabling translational repression. Viral carriers offer superior in vivo delivery compared to other methods like transfection. miRNA Viral Vectors can be applied for:
Case Study 1
In this study, researchers investigated the role of miRNA viral vectors in understanding the mechanisms underlying Fusobacterium nucleatum-induced colorectal cancer (CRC). They observed that F. nucleatum infection led to elevated expression of microRNA-31 (miR-31) in CRC tissues and cells, promoting tumorigenicity. Through miR-31, F. nucleatum inhibited autophagic flux by targeting syntaxin-12 (STX12), facilitating its intracellular survival. Additionally, miR-31 overexpression in CRC cells enhanced tumorigenicity by targeting eukaryotic initiation factor 4F-binding protein 1/2 (eIF4EBP1/2). Conversely, miR-31 knockout mice displayed resistance to CRC tumor formation. These findings underscore the role of miR-31 as a potential diagnostic biomarker and therapeutic target in CRC patients with F. nucleatum infection.
Figure 1. The impact of miR-31 on tumor growth was investigated in tumor xenografts in nude mice. HCT116 cells were infected with Lv-anti-miR-31-5p, Lv-anti-NC, Lv-miR-31-5p, or Lv-NC for 72 hours. After 48 hours of puromycin screening, cells were collected and subcutaneously injected into female BALB/c nude mice. Tumor growth and general status were monitored over 60 days. Tumor volumes were calculated, and tissues were analyzed for Ki-67 immunostaining after euthanization. (Tang B, et al., 2023)
Case Study 2
Researchers explored the role of miR-22 in aortic dissection (AD) and its impact on vascular smooth muscle cell (VSMC) apoptosis. They investigated miR-22 expression in human aortas and manipulated its levels in VSMCs using mimic, inhibitor, or siRNA plasmids. Bioinformatics analysis identified p38MAPKα as a miR-22 target. Inhibiting p38MAPKα expression reversed the apoptosis induced by miR-22 downregulation. Knockdown of miR-22 in a mouse AD model accelerated AD development. These findings highlight miR-22's potential as a therapeutic target for AD by modulating VSMC apoptosis through the MAPK signaling pathway, emphasizing the significance of vascular remodeling and VSMC function in AD pathogenesis.
Figure 2. The research findings demonstrate that adenovirus-mediated miR-22 modulation induces apoptosis in HASMCs. Additionally, the study reveals significant alterations in p38 expression following miR-22 treatment, highlighting the regulatory role of miR-22 in MAPK signaling pathways. (Xiao Y, et al., 2020)
Q: How does the quality of Creative Biogene's miRNA viral vectors compare to other suppliers?
A: Creative Biogene's miRNA viral vectors stand out for their exceptional quality and reliability. We employ stringent quality control measures throughout the vector production process to ensure purity, stability, and consistency, resulting in highly efficient and reproducible transfection outcomes.
Q: What advantages do Creative Biogene's miRNA viral vectors offer over competitors?
A: Our miRNA viral vectors boast several advantages over competitors, including high transfection efficiency, robust gene expression, and broad compatibility with various cell types. Additionally, our vectors are meticulously engineered to minimize off-target effects and maximize specificity, providing researchers with confidence in their experimental results.
Q: How does Creative Biogene ensure the safety of its miRNA viral vectors?
A: At Creative Biogene, safety is our top priority. We adhere to stringent biosafety protocols and regulations to guarantee the safety of our miRNA viral vectors. Our production facilities are equipped with state-of-the-art technology, and all vectors undergo rigorous testing to ensure they meet the highest safety standards, providing researchers with peace of mind during experimentation.
Q: Can researchers rely on Creative Biogene's miRNA viral vectors for long-term studies?
A: Absolutely. Creative Biogene's miRNA viral vectors are designed for long-term and stable gene expression, making them ideal for both short-term and long-term studies. Our vectors exhibit excellent stability and maintain high expression levels over extended periods, enabling researchers to conduct comprehensive investigations with confidence.
| Cat.No. | Product Name | Price |
|---|---|---|
| MIAHS0010 | pAdeno-hsa-let-7c | Inquiry |
| MIAHS0011 | pAdeno-hsa-let-7d | Inquiry |
| MIAHS0012 | pAdeno-hsa-let-7e | Inquiry |
| MIAHS0014 | pAdeno-hsa-miR-15a | Inquiry |
| MIAHS0016 | pAdeno-hsa-miR-16 | Inquiry |
| MIAHS0018 | pAdeno-hsa-miR-17 | Inquiry |
| MIAHS0020 | pAdeno-hsa-miR-17* | Inquiry |
| MIAHS0022 | pAdeno-hsa-miR-18a | Inquiry |
| MIAHS0024 | pAdeno-hsa-miR-19a | Inquiry |
| MIAHS0026 | pAdeno-hsa-miR-19b | Inquiry |
| MIAHS0028 | pAdeno-hsa-miR-20a | Inquiry |
| MIAHS0030 | pAdeno-hsa-miR-21 | Inquiry |
| MIAHS0031 | pAdeno-hsa-miR-22 | Inquiry |
| MIAHS0032 | pAdeno-hsa-miR-23a | Inquiry |
| MIAHS0034 | pAdeno-hsa-miR-24-1* | Inquiry |
Copyright © Creative Biogene. All rights reserved.